Original language | English (US) |
---|---|
Article number | 380 |
Journal | Neurology: Neuroimmunology and NeuroInflammation |
Volume | 4 |
Issue number | 5 |
DOIs | |
State | Published - 2017 |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Neurology: Neuroimmunology and NeuroInflammation, Vol. 4, No. 5, 380, 2017.
Research output: Contribution to journal › Short survey › peer-review
}
TY - JOUR
T1 - Lipoic acid pharmacokinetics at baseline and 1 year in secondary progressive MS
AU - Bittner, Frank
AU - Murchison, Charles
AU - Koop, Dennis
AU - Bourdette, Dennis
AU - Spain, Rebecca
N1 - Funding Information: From the VA Portland Health Care System (F.B., C.M., D.B., R.S.), OR; and Oregon Health & Science University (F.B., C.M., D.K., D. B., R.S.), Portland. Author contributions: Frank Bittner: manuscript writing. Charles Murchison: statistical analysis and manuscript editing. Dennis Koop: data collection and manuscript editing. Dennis Bourdette: data interpretation. Rebecca Spain: data collection, data interpretation, and manuscript editing. Acknowledgment: Pure Encapsulations, Sudbury, MA, provided the lipoic acid and placebo. Study funding: Department of Veterans Affairs (B7493-W, R. Spain), National Institutes of Health (UL1TR000128). Disclosure: F. Bittner received travel funding from the National Multiple Sclerosis Society. C. Murchison received research support from NINDS. D. Koop served on the editorial board for Drug Metabolism and Disposition. D. Bourdette received travel funding from the National Multiple Sclerosis Society, Consortium of MS Centers, and Paralyzed Veterans of America; is on the editorial board for Neurology; holds a patent for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin; has a patent pending for thyromimetic drugs for stimulating remyelination in multiple sclerosis; consulted for Magellan Health, Best Doctors, inc; and received research support from the National MS Center. R. Spain received research support from Biogen, Department of Veterans Affairs, Oregon Clinical and Translational Research Institute, VA Portland Health Care System, Oregon Health & Science University, and National MS Society, Conrad Hilton Foundation, Medical Research Foundation of Oregon, Race to Erase MS. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by the authors.
PY - 2017
Y1 - 2017
UR - http://www.scopus.com/inward/record.url?scp=85029078665&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029078665&partnerID=8YFLogxK
U2 - 10.1212/NXI.0000000000000380
DO - 10.1212/NXI.0000000000000380
M3 - Short survey
AN - SCOPUS:85029078665
SN - 2332-7812
VL - 4
JO - Neurology: Neuroimmunology and NeuroInflammation
JF - Neurology: Neuroimmunology and NeuroInflammation
IS - 5
M1 - 380
ER -